Update on insulin management in type 2 diabetes

Diabetes Spectrum

Volumn 22, Issue 2, 2009, Pages 85-91

  Neumiller, Joshua J ^a   Odegard, Peggy Soule ^c   Wysham, Carol H ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Rockwood Clinic   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN;

ADD ON THERAPY; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG COST; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAXIMUM PLASMA CONCENTRATION; MEAL; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; SELF MONITORING; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 66749151971     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.22.2.85     Document Type: Review

References (35)

1. Chan JL, Abrahamson MJ: Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc 78:459-467, 2003 (Pubitemid 36373947)
2. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 (Suppl. 3):S18-S24, 2002
3. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L, for the International DAWN Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28:2673-2679, 2005 (Pubitemid 43951158)
4. American College of Endocrinology/ American Association of Clinical Endocrinologists: Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 (Suppl. 1):3-68, 2007
5. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985 (Pubitemid 15134779)
6. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E: Improved beta cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol 118:365-373, 1988 (Pubitemid 18174152)
7. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng JP: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care 27:2597-2602, 2004 (Pubitemid 39441457)
8. Davidson MB: Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 28:222-224, 2005 (Pubitemid 40095806)
9. ACE/AACE Diabetes Road Map Task Force 2007: Road maps to achieve glycemic control in type 2 diabetes mellitus. Endocr Pract 13:260-268, 2007. Available online from http://www.aace.com/meetings/consensus/ odimplementation/roadmap. pdf. Accessed 25 November 2008
10. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 31 (Suppl. 1):S12-S54, 2008
11. Hirsch I: Insulin analogues. N Engl J Med 352:174-183, 2005 (Pubitemid 40096614)
12. Eli Lilly and Co.: Humalog prescribing information. Available online from http:// pi.lilly.com/us/humalog-pen-pi.pdf. Accessed 8 December 2008
13. Novo Nordisk: Novolog prescribing information. Available online from http://www. novblog.com/NovoLog-Prescribing-Info. pdf. Accessed 8 December 2008
14. Sanofi-Aventis: Apidra prescribing information. Available online from http://products. sanofi-aventis.us/apidra/apidra.pdf. Accessed 8 December 2008
15. Rassam AG, Zeise TM, Burge MR, Schade DS: Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care 22:133-136, 1999 (Pubitemid 29028309)
16. Mudaliar SR, Lindberg FA, Joyce M, Beersdsen P, Strange P, Lin A, Henry RR: Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin. Diabetes Care 22:1501-1506, 1999
17. Heise T, Nosek L, Biilmann Ronn B, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614-1619, 2004 (Pubitemid 38697678)
18. Eli Lilly and Co.: Humalog 75/25 prescribing information. Available online from http:// pi.lilly.com/us/humalog7525-pi.pdf. Accessed 8 December 2008
19. Eli Lilly and Co.: Humalog 50/50 prescribing information. Available online from http:// pi.lilly.com/us/humalog5050-pi.pdf. Accessed 8 December 2008
20. Novo Nordisk: Novolog Mix 70/30 prescribing information. Available online from http://www.novologmix70-30.com/ NovoLogMix7030-PI.pdf. Accessed 8 December 2008
21. Riddle MC, Rosenstock J, Gerich J, for the Insulin Glargine 4002 Study Investigators: The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086, 2003
22. Fritsche A, Schweitzer MA, Haring HU, for the 4001 Study Group: Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 138:952-959, 2003
23. Massi Benedetti M, Humburg E, Dressler A, Zieman M: A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35:189-196, 2003 (Pubitemid 36577862)
24. Kennedy L, Herman WH, Strange P, Harris A, for the GOAL A1C Team: Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (Goal A1C) trial. Diabetes Care 29:1-8, 2006 (Pubitemid 44033422)
25. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S, Hanninen J, Levanen H, Lahdenpera S, Lehtonen R, Ryysy L: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442-451, 2006 (Pubitemid 43277866)
26. Standl E, Maxeiner S, Raptis S, for the HOE901/4009 Study Group: Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 38:172-177, 2006
27. Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J, for the HOE901/4013 LA Study Group: Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 37:495-501, 2006
28. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P, on behalf of the Levemir Treat-to-Target Study Group: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin- naïve people with type 2 diabetes. Diabetes Care 29:1269-1274, 2006 (Pubitemid 44125921)
29. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28:1569-1581, 2006 (Pubitemid 44856694)
30. Tibaldi J: Initiating and intensifying insulin therapy in type 2 diabetes mellitus. Am J Med 121:S20-S29, 2008
31. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P: Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 17:307-313, 2003 (Pubitemid 37315939)
32. Kabadi UM, Kabadi M: Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract 72:265-270, 2006 (Pubitemid 43729134)
33. Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P: Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Invest Med 55:62-68, 2007 (Pubitemid 46723943)
34. Mooradian AD, Bernbaum M, Albert SG: Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 145:125-134, 2006 (Pubitemid 46780586)
35. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB: A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 23:78-86, 2005 (Pubitemid 40965048)